The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100.
1/50 - 1/100. Predicted molecular weight: 63 kDa.
Cleaves the alpha-chain at multiple sites and the beta-chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and therefore does not initiate the formation of the fibrin clot and does not cause the fibrinolysis directly. It does not cleave (activate) prothrombin and plasminogen but converts the inactive single chain urinary plasminogen activator (pro-urokinase) to the active two chain form. Activates coagulation factor VII.
Belongs to the peptidase S1 family. Contains 3 EGF-like domains. Contains 1 kringle domain. Contains 1 peptidase S1 domain.
Proteolytic cleavage at Gly-23 or Met-27 can give rise to the 50 kDa heavy chain and cleavage at Arg-313 or Lys-319 can give rise to the 27 kDa light chain. The heavy chain can undergo further proteolytic cleavage at Lys-169 or Arg-170 to give rise to 2 inactive 26 kDa fragments and the light chain can undergo further proteolytic cleavage at Arg-480 to give rise to inactive 17 kDa and 8 kDa fragments.
Secreted. Secreted as an inactive single-chain precursor and is then activated to a heterodimeric form.
Immunohistochemistry analysis of formalin fixed and paraffin embedded Human hepatocarcinoma tissue labeling HABP2 using ab174953 at a 1/50 dilution, followed by peroxidase conjugation of the secondary antibody and DAB staining.
Western blot - Anti-HABP2 antibody (ab174953)
Anti-HABP2 antibody (ab174953) at 1/50 dilution + Mouse liver tissue lysate at 35 µg